ArticleBMC cancer2013

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia.

Andrew M Stein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.